Lefamulin: Phase III started

Nabriva began the double-blind, placebo-controlled, international Phase III LEAP 2 trial to compare 600 mg oral lefamulin twice daily for 5 days vs. 400 mg oral moxifloxacin once daily for 7 days in a...